Uso de Omalizumab en cuadro asmático-grave (Use of Omalizumab in severe asthma)
Resumen
Asma entendido como una patología crónica de carácter inflamatorio etiológicamente multifactorial inducido por hiperreactividad bronquial acompañado por broncoconstricción, desencadenado por reacción alérgica a los múltiples agentes alérgenos aunque puede desencadenarse inclusive sin reacción alérgica, así mismo la inflamación es de índole eosinofílico o no eosinofílica, así como las comorbilidades pueden modificar en demasía la presentación clínica de la enfermedad tomando en cuenta la frecuencia de las exacerbaciones y respuesta terapéutica. Asma grave denominado como aquel que requiere de dosificación alta de corticoides inhalados, acompañado de fármacos coadyuvantes para mantener estable la sintomatología, es aquí cuando planteamos Omalizumab un anticuerpo monoclonal humanizado donde su finalidad es la inhibición de la inmunoglobulina E, bajando el conteo de ésta en sangre mejorando el cuadro. El asma grave como patología de carácter inflamatorio crónico se a convertido en un problema alarmante de salud a no responder instancias finales de tratamiento por lo cual se ha visto la necesidad apoyarse en terapias biológicas como lo es Omalizumab la cual actúa como un coadyuvante a la terapia regular de altas dosis de corticosteroides inhalados la cual se la emplea de forma subcutánea con dosis dependientes del peso y conteo de IgE basal del paciente en la cual inhibe al aumento en conteo de IgE libre al unirse a el dominio Cε3 región Fc de la membrana de la misma inmunoglobulina creando así un complejo anti-IgE evitando toda interacción con receptores para las células inmunológicas inflamatorias mejorando la sintomatología del paciente.
Descargas
Citas
Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P. Targeted therapy in severe asthma today: Focus on immunoglobulin E. Drug Des Devel Ther. 2017;11:1979–87.
Cataldo D, Louis R, Michils A, Peché R, Pilette C, Schleich F, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma [Internet]. 2021;58(4):448–58. Available from: https://doi.org/10.1080/02770903.2019.1705335
Canonica GW, Rottoli P, Bucca C, Zappa MC, Michetti G, Macciocchi B, et al. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: The real life observational PROXIMA study. World Allergy Organ J [Internet]. 2018;11(1):1–11. Available from: https://doi.org/10.1186/s40413-018-0214-3
Tortajada-Girbés M, Bousquet R, Bosque M, Carrera Martínez JJ, Ibáñez MD, Moreira A, et al. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma. Expert Rev Respir Med [Internet]. 2018;12(9):745–54. Available from: https://doi.org/10.1080/17476348.2018.1507740
Kirchnerová OR, Valena T, Novosad J, Teřl M. Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic. Postep Dermatologii i Alergol [Internet]. 2019;36(1):34–43. Available from: https://doi.org/10.5114/ada.2018.76606
Adachi M, Kozawa M, Yoshisue H, Lee Milligan K, Nagasaki M, Sasajima T, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respir Med [Internet]. 2018;141(April):56–63. Available from: https://doi.org/10.1016/j.rmed.2018.06.021
Karina Jahnz-Różyk et al. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulm Med [Internet]. 2018;48(1):1–9. Available from: https://doi.org/10.1186/s12890-018-0610-z
Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergol Int [Internet]. 2020;69(2):167–77. Available from: https://doi.org/10.1016/j.alit.2020.01.004
Arrobas A, Barbosa MP, Rabiais S, Vandewalle B, Félix J. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients. Pulmonology [Internet]. 2021;27(2):124–33. Available from: https://doi.org/10.1016/j.pulmoe.2020.03.001
Pałgan K, Zbikowska-Götz M, Lis K, Chrzaniecka E, Bartuzi Z. Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma. Postep Dermatologii i Alergol [Internet]. 2018;35(5):495–7. Available from: https://doi.org/10.5114/ada.2018.77241
Ahmed H, Turner S. Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol [Internet]. 2019;54(6):778–87. Available from: https://doi.org/10.1002/ppul.24317
Côté A, Godbout K, Boulet LP. The management of severe asthma in 2020. Biochem Pharmacol [Internet]. 2020;179:114112. Available from: https://doi.org/10.1016/j.bcp.2020.114112
Franken Morales SS, Garcia Orrego AM, Pabón Bonilla D. Actualización del asma. Rev Medica Sinerg [Internet]. 2021;6(10):e717. Available from: https://doi.org/10.31434/rms.v6i10.717
Huang WC, Fu PK, Chan MC, Chin CS, Huang WN, Lai KL, et al. The long-term effectiveness of omalizumab in adult patients with severe allergic asthma: Continuous treatment versus boosting treatment. J Clin Med. 2021;10(4):1–11.
Menzella F, Ghidoni G, Galeone C, Capobelli S, Scelfo C, Facciolongo NC. Immunological aspects related to viral infections in severe asthma and the role of omalizumab. Biomedicines [Internet]. 2021;9(4). Available from: https://doi.org/10.3390/biomedicines9040348
Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, et al. Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. Allergy Rhinol. 2018;9:215265671876338.
Álvarez-Gutiérrez FJ, Blanco-Aparicio M, Plaza V, Cisneros C, García-Rivero JL, Padilla A, et al. Consensus Document for Severe Asthma in Adults. 2020 Update. Open Respir Arch [Internet]. 2020;2(3):158–74. Available from: https://doi.org/10.1016/j.opresp.2020.03.005
Brooks EA, Massanari M, Hanania NA, Weiner DJ. Cost-effectiveness of fractional exhaled nitric oxide (Feno) measurement in predicting response to omalizumab in asthma. Clin Outcomes Res [Internet]. 2019;11:301–7. Available from: doi: 10.2147/CEOR.S177207
Singh H, Peters JI, Kaur Y, Maselli DJ, Diaz JD. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study. Ann Allergy, Asthma Immunol [Internet]. 2019;123(5):476-482.e1. Available from: https://doi.org/10.1016/j.anai.2019.07.026
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, et al. Omalizumab for severe allergic asthma treatment in Italy: A cost-effectiveness analysis from proxima study. Risk Manag Healthc Policy [Internet]. 2020;13:43–53. Available from: https://doi.org/10.2147/RMHP.S211321
Hutyrová B, Bystroň J. The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: Real-life experience from the Czech Anti-IgE Registry. Postep Dermatologii i Alergol [Internet]. 2018;35(5):510–5. Available from: https://doi.org/10.5114/ada.2018.77241
Vaník P, Novosad J, Kirchnerová O, Krčmová I, Teřl M. Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry. Allergy, Asthma Clin Immunol [Internet]. 2020;16(1):1–16. Available from: https://doi.org/10.1186/s13223-020-00479-1
Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract [Internet]. 2019;7(1):156-164.e1. Available from: https://doi.org/10.1016/j.jaip.2018.04.043
Loureiro CC, Amaral L, Ferreira JA, Lima R, Pardal C, Fernandes I, et al. Omalizumab for severe asthma: Beyond allergic asthma. Biomed Res Int [Internet]. 2018;2018:1–10. Available from: https://doi.org/10.1155/2018/3254094
Tabatabaian F, Ledford DK. Omalizumab for severe asthma: Toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy [Internet]. 2018;11:53–61. Available from: https://doi.org/10.2147/JAA.S107982
Tadrous M, Khuu W, Lebovic G, Stanbrook MB, Martins D, Paterson JM, et al. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Ann Allergy, Asthma Immunol [Internet]. 2018;120(1):59-65.e2. Available from: https://doi.org/10.1016/j.anai.2017.08.016
Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. Pharmacoeconomics [Internet]. 2018;36(10):1165–200. Available from: https://doi.org/10.1007/s40273-018-0668-8
Silva E. MD. DL, Ramírez Z., MD. LF, Serrano R., MD. CD. Anticuerpos monoclonales para el manejo del asma: de las guías a la medicina personalizada. Rev Colomb Neumol. 2016;28(2):78–93.
Aires B. Asma: introducción, epidemiología y conceptos. Rev ARGENTINA Med / [Internet]. 2022;10(2):5–9. Available from: https://www.revistasam.com.ar/index.php/RAM/article/view/708/603
Sally Wenzel M. Treatment of severe asthma in adolescents and adults - UpToDate. UptodateCom [Internet]. 2021;1–43. Available from: https://www.uptodate.com/contents/treatment-of-severe-asthma-in-adolescents-and-adults?search=tratamiento farmacologico asma&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3
Derechos de autor 2022 Marlon Javier González Velastegui ; David Washington Arias Calvache
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
